Patrik Brundin (Former)
131 – 140 of 248
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2005
-
Mark
Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction.
(
- Contribution to journal › Article
-
Mark
The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient {beta}-cell mass and exocytosis.
(
- Contribution to journal › Article
-
Mark
Platelet-Derived Growth Factor (PDGF-BB) and Brain-Derived Neurotrophic Factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions.
(
- Contribution to journal › Article
-
Mark
The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.
(
- Contribution to journal › Article
-
Mark
Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice.
(
- Contribution to journal › Article
-
Mark
Stem cell-based therapy for Parkinson's disease.
(
- Contribution to journal › Scientific review
-
Mark
Increased fiber outgrowth from xeno-transplanted human embryonic dopaminergic neurons with co-implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor.
(
- Contribution to journal › Article
-
Mark
Orexin loss in Huntington's disease.
(
- Contribution to journal › Article
-
Mark
Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway
(
- Contribution to journal › Article
-
Mark
Synaptic dysfunction in Huntington's disease: a new perspective
(
- Contribution to journal › Scientific review